Search for content, post, videos

Companies Reach Commercialization Deal


Helsinn Group and Denmark’s Pharmacosmos A/S announced that they have reached an agreement for the exclusive U.S. commercialization rights to Monofer®, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia.

Helsinn received the exclusive rights to commercialize Monofer® and any other iron isomaltoside 1000 products developed by Pharmacosmos in the US.  Pharmacosmos is eligible for milestone payments of up to $130 million USD  for Monofer® in iron deficiency anemia in the U.S.  Pharmacosmos also will be eligible to receive further payments for the manufacture and supply of Monofer® to Helsinn in the US.

Pharmacosmos is known for developing and marketing drugs for treating  iron deficiency anemia.